Loading
A phase 1/2 trial of GSK4418959 in colorectal cancer and endometrial cancer, run by GlaxoSmithKline, active and no longer recruiting.
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT06710847 by GlaxoSmithKline, with 14 participants enrolled, started 2024-12-13 and due to reach its primary completion in 2026-06-22. Interventions recorded: GSK4418959 and PD-1 inhibitor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares GSK, Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer and the tag pipeline.
Shares GSK, Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer and the tag pipeline.
Shares Mismatch-repair-deficient endometrial cancer, GSK, Endometrial cancer and the tag pipeline.
Shares GSK, Endometrial cancer and the tag pipeline.
Shares Mismatch-repair-deficient endometrial cancer, Endometrial cancer and the tag pipeline.
Shares GSK, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/